The U.S. federal government has approved a series of clinical trials to evaluate the potential of a cannabis flavonoid from a rare Jamaican cannabis variety, Black Swan, for the treatment of pancreatic cancer.
Research usually focuses on the therapeutic properties of cannabinoids such as CBD and THC. Last summer, however, a study published in the journal Frontiers in Oncology reported that cannflavin B. Which is a flavonoid in cannabis, may help kill cancer cells in the pancreas. In fact , Pancreatic cancer is one of the most deadly forms of cancer, with a survival rate of 8%.
In this study, researchers found that cannflavin B can cause cancer cells to “commit suicide”, apoptosis, while improving the effectiveness of standard chemotherapy and radiotherapy. So the company Flavocure Biotech Inc. which funded this research, however, will not use natural cannabis to fight cancer. But the synthetic version of cannflavin B, to develop an anti-cancer drug known as Caflanone, or FBL-03G.
The Food and Drug Administration (FDA) granted Caflanone orphan drug status this autumn, allowing Flavocure to launch its future phase of trials. Orphan drug status reserved in the United States for new drugs that can treat diseases affecting fewer than 200,000 Americans a year.
Research continues at Harvard Medical School, an institution known for developing some of the world’s most successful drugs. Said Clark Swanson, co-founder and executive vice president of Flavocure. The New Drug Identification (IND) studies are essentially complete now, therefore, we are confident that the results and the highly clinical stage of our company’s drug development are on track. »
Although the company is working to create a synthetic derivative of cannabis, the initial discovery of this anti-cancer flavonoid came from a unique strain of Jamaican ganja. The president of Flavocure, Dr. Henry Lowe Ph.D. discovered a rare strain of cannabis endemic to Jamaica. The strain was named “Black Swan” because of its rich flavonoid spectrum. »
Chrysoeriol, a second flavonoid from this variety, is also promising for the treatment of acute myeloid leukemia (AML). Flavor received FDA approval in 2018 to launch research, which is not yet finalized.
Clinical trials for pancreatic cancer expected to begin in the spring of 2020. For the time being, we plan to conduct a multi-site study on both the east and west coasts of the United States. »